(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

CELLARES

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

CELLARES

ST13

US500000088446115

Class

9, 40, 42, 44

Filing

88446115

Registration

7164348

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

59

Latest update

07/23/2024

Trademark type

Word

Nice classes

9, 40, 42, 44

Filing date

05/24/2019

Registration date

09/12/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

09/12/2023

Last transaction

07/23/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

2023-04-00

First use in commerce

2023-04-00

Drawing code

4

Owner type

03

Owner location

San Francisco, CA, US

Examiner

TAYLOR, DAVID T

Law office

M30

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

C. C. (pessoa física)
C. C. (pessoa física)

Representatives

Bobby A. Ghajar Cooley LLP

Technical classification

Nice Classes

Class 9Class 40Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 9

Downloadable software applications for telephonestabletscomputers allowing the access to information and consulting in the field of health; Downloadable software applications for telephonestabletscomputers allowing the access to informationmonitoring and management systems for the manufacture of advanced therapy and cell therapy medications; Downloadable databases in the field of manufacture of advanced therapy and cell therapy medications; none of the foregoing in the field of pharmaceutical and veterinary products

Class 40

Custom manufacture of therapeutic drugscustom manufacture of cell therapies and cancer therapies

Class 42

Medical and scientific research information in the field of cell therapy; Medical and scientific research in the field of cell therapy; Hosting digital content for users account in the Internet in the medical field and manufacturing of advanced therapy and cell therapy medications fields

Class 44

Cell therapy services for the treatment of hematological malignancies

Publications

History of USPTO decisions and trademark events.

59 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

07/22/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

07/22/2024

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

07/22/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

09/12/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

09/12/2023

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

08/11/2023

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

08/10/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

07/12/2023

IUAF

USE AMENDMENT FILED

05/25/2023

EISU

TEAS STATEMENT OF USE RECEIVED

05/25/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

11/23/2022

EX5G

SOU EXTENSION 5 GRANTED

11/22/2022

EXT5

SOU EXTENSION 5 FILED

11/16/2022

EEXT

SOU TEAS EXTENSION RECEIVED

11/16/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

09/27/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

09/27/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

09/27/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

09/27/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

09/27/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

05/19/2022

EX4G

SOU EXTENSION 4 GRANTED

05/17/2022

EXT4

SOU EXTENSION 4 FILED

05/17/2022

EEXT

SOU TEAS EXTENSION RECEIVED

05/17/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

02/07/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

02/07/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

02/07/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

07/24/2021

EX3G

SOU EXTENSION 3 GRANTED

07/22/2021

EXT3

SOU EXTENSION 3 FILED

07/22/2021

EEXT

SOU TEAS EXTENSION RECEIVED

07/22/2021

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

03/10/2021

EX2G

SOU EXTENSION 2 GRANTED

03/08/2021

EXT2

SOU EXTENSION 2 FILED

03/08/2021

EEXT

SOU TEAS EXTENSION RECEIVED

03/08/2021

NOAC

CORRECTED NOA E-MAILED

01/20/2021

DPCC

DIVISIONAL PROCESSING COMPLETE

01/15/2021

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

01/07/2021

DRRR

DIVISIONAL REQUEST RECEIVED

12/09/2020

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

12/09/2020

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

07/10/2020

EX1G

SOU EXTENSION 1 GRANTED

07/08/2020

EXT1

SOU EXTENSION 1 FILED

07/08/2020

EEXT

SOU TEAS EXTENSION RECEIVED

07/08/2020

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

05/26/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

03/31/2020

PUBO

PUBLISHED FOR OPPOSITION

03/31/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/11/2020

ALIE

ASSIGNED TO LIE

02/27/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

02/21/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

02/15/2020

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

02/14/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

02/14/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/14/2020

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/17/2019

GNRT

NON-FINAL ACTION E-MAILED

08/17/2019

CNRT

NON-FINAL ACTION WRITTEN

08/17/2019

DOCK

ASSIGNED TO EXAMINER

08/13/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/10/2019

NWAP

NEW APPLICATION ENTERED

05/28/2019

Continuous trademark protection

Get notified about every new filing that threatens CELLARES or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.